Refer to the clinical prior authorizations implemented in traditional Medicaid.

Managed care organizations have the option to use any clinical prior authorization approved by the Texas Drug Utilization Review Board. The Pharmacy Clinical Prior Authorization Assistance Chart (PDF) shows the prior authorization each MCO uses and how those authorizations relate to the authorizations used for traditional Medicaid claim processing. This chart is updated quarterly. Providers can also refer to MCO Resources for links to each MCO's clinical prior authorizations.

Clinical prior authorizations required by MCOs to perform for people enrolled in Medicaid include:

  1. Cystic Fibrosis Agents (PDF)
    • Only Orkambi criteria are required
  2. Hepatitis C Virus (initial) (PDF)
  3. Hepatitis C Virus (refill)(PDF)
  4. Promethazine/Promethazine Containing Products (PDF)
  5. Synagis (PDF)

The following clinical prior authorizations are those MCOs have the option to perform for people enrolled in Medicaid or CHIP.

  1. ADD/ADHD Medications (PDF)
  2. Alinia (nitazoxanide) (PDF)
  3. Aliskiren-Containing Agents (except Valturna) (PDF)
  4. Allergen Extracts - Oralair (PDF)
  5. Altabax (retapamulin) (PDF)
  6. Androgenic Agents (PDF)
  7. Antipsychotics (PDF)
  8. Antiemetics (PDF)
  9. Anxiolytics and Sedatives/Hypnotics (PDF)
  10. Arikayce (PDF)
  11. Binge Eating Disorder (BED) Agents (PDF)
  12. Buprenorphine Agents (PDF)
  13. Calcitonin Gene-Related Peptide Receptor (CGRP) Antagonists (PDF)
  14. Calcitonin Gene-Related Peptide Receptor (CGRP) Antagonists, Chronic (PDF)
  15. Carisoprodol Overuse (PDF)
  16. Carisoprodol-Containing Agents (PDF)
  17. Central Nervous System Stimulants (PDF)
  18. Colcrys (colchicine) (PDF)
  19. Copaxone (glatiramer) (PDF)
  20. Cough and Cold Medications (PDF)
  21. COX-2 Inhibitors (PDF)
  22. Cyclobenzaprine (PDF)
  23. Cymbalta (duloxetine) (PDF)
  24. Cystic Fibrosis Agents (PDF)
  25. Cytokine and CAM Antagonists (PDF)
  26. Desmopressin (PDF)
  27. Dextromethorphan Overutilization (PDF)
  28. Diabetic Test Strips (PDF)
  29. Diacomit (PDF)
  30. Diclofenac (PDF)
  31. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (PDF)
  32. Doxylamine/Pyridoxine (PDF)
  33. Drug Regimen Optimization (PDF)
  34. Dupixent (PDF)
  35. Duplicate Therapy (PDF)
  36. Emflaza (PDF)
  37. Epidiolex (PDF)
  38. Enzymes (PDF)
  39. Erythropoiesis-Stimulating Agents (PDF)
  40. Fentanyl Agents (PDF)
  41. Flexeril/Amrix (cyclobenzaprine) (PDF)
  42. Forteo (teriparatide) (PDF)
  43. Gabapentin Agents (PDF)
  44. Gaucher's Disease Agents (PDF)
  45. GI Motility Agents (PDF)
  46. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (PDF)
  47. Growth Hormones (PDF)
  48. Hereditary Angioedema (PDF)
  49. H.P. Acthar (PDF)
  50. Imiquimod (PDF)
  51. Increlex (mecasermin) (PDF)
  52. Inhaled Antibiotics (PDF)
  53. Ketorolac (Toradol) (PDF)
  54. Keveyis (PDF)
  55. Leukotriene Modifiers (PDF)
  56. Llidocaine Patches (PDF)
  57. Lovaza (omega-3-acid ethyl esters) (PDF)
  58. Lyrica (pregabalin) (PDF)
  59. Makena (PDF)
  60. Monoclonal Antibody Agents for Asthma (PDF)
  61. Neutontin (Gabapentin) Agents (PDF)
  62. Nuedexta (dextromethorphan/quinidine) (PDF)
  63. Nuplazid (PDF)
  64. Ophthalmic Immunomodulators (PDF)
  65. Opiate Overutilization (PDF)
  66. Opiate/Benzodiazepine/Muscle Relaxant Combinations (PDF)
  67. Oriahnn (PDF)
  68. Orilissa (PDF)
  69. Oxervate (PDF)
  70. Oxycodone Extended-Release Products (PDF)
  71. Palforzia (PDF)
  72. PCSK9 Inhibitors (PDF)
  73. Phosphodiesterase 5 (PDE5) Inhibitors  (PDF)
  74. Phosphate Binders (PDF)
  75. Plavix (clopidogrel) (PDF)
  76. Propylthiouracil (PDF)
  77. Proton Pump Inhibitors (PDF)
  78. Pulmonary Arterial Hypertension (PDF)
  79. Ranexa (PDF)
  80. Savella (milnacipran) (PDF)
  81. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors (PDF)
  82. Symlin (pramlintide Acetate) (PDF)
  83. Synagis (palivizumab) (PDF)
  84. Thiazolidinediones (PDF)
  85. Topical Acne Agents (PDF)
  86. Topical Immunomodulators (PDF)
  87. Topical Retinoids (PDF)
  88. Transthyretin Agents (PDF)
  89. Urea Cycle Disorder Agents (PDF)
  90. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors (PDF)
  91. Wakix (PDF)
  92. Xifaxan (rifaximin) (PDF)
  93. Xyrem/Xywav (PDF)
  94. Zelboraf (vemurafenib) (PDF)